Navigation Links
REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011
Date:1/27/2011

DURECT will receive royalties for REMOXY and the other licensed drug candidates of between 6.0% to 11.5% of net sales of the drug candidate depending on sales volume as well as a mark-up on DURECT's supply of key excipients used in the manufacture of the licensed drug candidates.  Pain Therapeutics sublicensed the commercialization rights of REMOXY and other licensed drug candidates to King Pharmaceuticals in November 2005.  In October 2010, Pfizer Inc. (NYSE: PFE) announced that it had entered into a definitive merger agreement to acquire King.  Should that transaction be completed, Pfizer would assume the development and commercialization rights and obligations to REMOXY and to the other licensed ORADUR-based opioids.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR™, and TRANSDUR™-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR™, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding REMOXY, its poten
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. REMOXY® New Drug Application Resubmitted
2. King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY®
3. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
4. K-V Pharmaceutical Company Updates Status of New Drug Application for Gestiva™
5. CoreLab Partners Launches Advanced Imaging Application
6. Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices Offers Sessions on Orthopedic and Cardio Applications
7. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
8. Unilife Receives SPP Applications Exceeding A$12.8 Million
9. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
10. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
11. Pfizer Submits Applications to FDA and EMA for Use of its Pneumococcal Conjugate Vaccine, Prevnar 13®, in Adults 50 and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... ATLANTA , May 23, 2013  Inhibikase ... treatments, announced today that it will present new ... at an industry conference sponsored by the PML ... Biogen Idec).  JC polyomavirus (JCV) is the causative ... host-directed tyrosine kinase inhibitor in an extended release ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
(Date:5/23/2013)... San Francisco, CA (PRWEB) May 23, 2013 ... community safety outreach program being tackled by the Safe ... its second Fullpower personal safety workshop for ... develops and teaches personal safety skills programs for people ... been telling us their experiences with street harassment for ...
(Date:5/23/2013)... Lake City, Utah (PRWEB) May 23, 2013 ... Chevreau, PhD, R.D., published an article today on Tatalou.com ... an illness-free vacation. , The article, titled “ How ... why it’s important to carry hand sanitizer, when it’s ... to watch out for seafood, the importance of staying ...
(Date:5/23/2013)... 23, 2013 Dimensional Insight, a ... announced today that Paul Comras, director of ... at the 2013 International Medical Users Software Exchange ... & Revenue Visibility from Your General Ledger.” The ... from 2:30-3:25 p.m. in Azalea 1 at the ...
(Date:5/23/2013)... Alexandria, VA (PRWEB) May 23, 2013 Memorial ... start of the summer season for many Americans. Across the ... the long weekend. NHPCO encourages Americans to reach out to ... in military service. , As the nation marks Memorial Day ... Serious injuries and the untimely deaths of brave service men ...
(Date:5/23/2013)... To better serve the architecture ... pleased to announce the release of its new ... space division products. Provided by Koroseal, a leader ... patterns and colors represent a sophisticated response to ... a team of Koroseal experts, Modernfold reviewed hundreds ...
Breaking Medicine News(10 mins):Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 3Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 4Health News:How to Stay Healthy While Traveling 2Health News:Dimensional Insight to Demonstrate How Hospitals Can Use Business Intelligence within MEDITECH Environments at 2013 International MUSE Conference 2Health News:Memorial Day: Make it a Time of Remembrance and Support 2Health News:Memorial Day: Make it a Time of Remembrance and Support 3Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2
... treatment if they donate eggs for controversial cloning research.// ... for ‘egg sharing' so as to advance work on human ... this scheme and pass on their spare eggs to the ... by almost half. , ,The researcher team from ...
... of Agriculture have indicated the enhanced nutritive benefits of ... ,According to scientists, watermelons are a production ... the parent plant, which slows down once the melon ... 70 degrees, contained almost 40% of lycopene and 50 ...
... than with most modern antibiotics, according to a recent ... from the University of Bonn, Germany in collaboration with ... that medihoney is a very effective treatment for several ... infected with multi-resistant bacteria within a few weeks. ...
... and Channel 7 Indian Television network has raised many questions ... professionals. A cleaning up operation is long overdue to rejuvenate ... World Medical Association in 1949 - I ... of humanity …. I will practice my profession with conscience ...
... to an article that was published in the July 24 ... the JAMA/Archives journals, states that women who take// combination of ... have an increased risk of breast cancer. ... their normal levels of the testosterone hormone would be likely ...
... drug that is widely used in heart failure. Some ... is contraindicated. //However a new analysis shows that the ... heart failure. ,"Contrary to conventional wisdom, digitalis ... advances our understanding of both digitalis, the oldest known ...
Cached Medicine News:Health News:IVF Price To Be Reduced If Women Opt For Egg Sharing Scheme 2Health News:IVF Price To Be Reduced If Women Opt For Egg Sharing Scheme 3Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 2Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 3Health News:Maimed Conscience and Maimed Beggars (Medical Ethics in India) – Part 4Health News:Study Indicates An Increased Risk Of Breast Cancer In Women Undertaking Estrogen and Testosterone Therapy 2Health News:Digitalis Could Be Safe In Diastolic Heart Failure 2Health News:Digitalis Could Be Safe In Diastolic Heart Failure 3
Very compressive support for submental liposuction...
Applies pressure on scalp to stretch it before surgery...
Deluxe Abdominal Binders...
Ideal for abdominal, flank, hip and thigh procedures....
Medicine Products: